December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.710 -0.150 (-3.09%)
Streaming Delayed Price Updated: 10:54 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
21 22 Next >
News headline image
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? ↗
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals ↗
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
Via Benzinga
Topics Artificial Intelligence
News headline image
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024 ↗
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Is Recursion Pharmaceuticals a Millionaire-Maker? ↗
It's likely to experience a lot of growth. 
Via The Motley Fool
News headline image
99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks ↗
Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
News headline image
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? ↗
There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
25 Best Artificial Intelligence Stocks to Buy Right Now ↗
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why ↗
This article identifies the 
Via Talk Markets
Topics Artificial Intelligence
News headline image
3 Millionaire-Maker Artificial Intelligence (AI) Stocks ↗
For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
Is Recursion Pharmaceuticals Stock a Buy? ↗
The company is ambitious and exploring exciting areas, but it's still early in the game. 
Via The Motley Fool
News headline image
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell ↗
This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump. 
Via The Motley Fool
News headline image
3 Healthcare Stocks Injecting AI for Big Gains ↗
Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street ↗
Are the analysts right about these Nvidia-backed AI stocks? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia Is Buying Shares of These 5 AI Companies. Should You Do the Same? ↗
SoundHound AI, Arm, Nano-X, Recursion, and TuSimple are all in Nvidia's portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
News headline image
Why SoundHound AI Stock Lost 22% Last Month ↗
Check out why SoundHound AI's stock dropped in June, despite a complete lack of negative news. Is this AI stock a great buy today? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 ↗
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today ↗
 
Via Benzinga
News headline image
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet ↗
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
News headline image
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday ↗
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it plans... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.